Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis

Phase 2 Not yet recruiting 20 enrolled Anhui Provincial Cancer Hospital

Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a non-randomized, open-label, single-center clinical trial to evaluate efficacy and safety of sintilimab plus bevacizumab and chemotherapy on treatment in patients with advanced no liver metastatic MSS/pMMR colorectal cancer

Timeline

Start: 2025-05
Primary completion: 2026-02
Completion: 2027-12

Publications

Results Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, Yoshii T, Kotani D, Tamura H, Mikamoto Y, Hirano N, Wakabayashi M, Nomura S, Sato A, Kuwata T, Togashi Y, Nishikawa H, Shitara K. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020 Jun 20;38(18):2053-2061. doi: 10.1200/JCO.19.03296. Epub 2020 Apr 28.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Irinotecan	Small molecule	150 mg/m2	—
Subject	Oxaliplatin	Small molecule	130 mg/m2	—
Background	Bevacizumab	Monoclonal antibody	7.5 mg/kg	—
Background	Capecitabine	Small molecule	1250 mg/m2	—
Background	Sintilimab	Monoclonal antibody	200 mg	—

Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis

Summary

Timeline

Publications

Drugs

Indications